

# **A Comprehensive Clinical Template for ST-Elevation Myocardial Infarction (STEMI)**

---

### **Section I: Initial Evaluation and Diagnosis**

The initial evaluation of a patient with suspected ST-Elevation Myocardial Infarction (STEMI) is a time-critical process focused on rapid diagnosis and initiation of reperfusion therapy. The principle "time is muscle" underscores every action, as the extent of myocardial damage is directly related to the duration of coronary artery occlusion.1 The diagnostic framework rests on three pillars: a focused history, a targeted physical examination, and, most importantly, an immediate 12-lead electrocardiogram (EKG).

#### **A. Patient History**

A thorough yet focused history is essential to establish the pre-test probability of acute coronary syndrome (ACS) and to identify potential life-threatening mimics. While the classic presentation is well-described, a high index of suspicion must be maintained for atypical presentations, which are common and can lead to diagnostic delays.1

##### **Chief Complaint & History of Present Illness (HPI)**

The OPQRST mnemonic provides a structured framework for characterizing the patient's symptoms, particularly chest discomfort.3

* **Onset:** It is crucial to determine what the patient was doing when the symptoms began and whether the onset was sudden or gradual.3 STEMI pain often presents as a "crescendo" pain, with severity increasing over several minutes.9 An abrupt onset of maximal pain should raise suspicion for alternative diagnoses like aortic dissection.8  
* **Provocation/Palliation:** Inquire about factors that worsen or alleviate the symptoms.3 Ischemic chest pain from a STEMI is typically persistent and unrelenting, not relieved by rest, nitroglycerin, or changes in position.8 In contrast, pain that is pleuritic (worse with deep inspiration) or positional (worse when supine, improved by sitting up and leaning forward) is characteristic of acute pericarditis.10 Chest wall tenderness on palpation makes an acute myocardial infarction (MI) less likely.11  
* **Quality:** Ask the patient to describe the sensation in their own words before offering descriptors.6 Classic descriptions of ischemic pain include pressure, heaviness, tightness, squeezing, aching, or a crushing sensation.2 A sharp, "tearing," or "ripping" quality is a red flag for acute aortic dissection and demands immediate investigation.14  
* **Region/Radiation:** The pain is typically located in the substernal or left chest area.9 Ask specifically if the pain travels or radiates. Classic radiation patterns include the inner aspect of the left arm, both arms, the shoulders, neck, or jaw.9 Pain that radiates to the right arm/shoulder or to both arms is a particularly high-risk feature with a strong positive likelihood ratio for MI.11  
* **Severity:** Use a 0-10 pain scale to quantify the intensity of the pain at onset and at the time of evaluation.3 While severity is subjective, it provides a baseline for assessing response to therapy.  
* **Time:** Establish a precise timeline. Key questions include when the symptoms started and their duration.3 Ischemic pain associated with STEMI typically lasts longer than 15-20 minutes.9 This "symptom-onset-to-FMC (first medical contact)" time is a critical metric for determining reperfusion strategy.

##### **Associated Symptoms**

A checklist of associated symptoms is critical, as they can support the diagnosis of STEMI or point toward alternative etiologies.

* **Classic Ischemic Symptoms:** The presence of diaphoresis (profuse sweating), dyspnea (shortness of breath), nausea, vomiting, profound fatigue, palpitations, lightheadedness, anxiety, or a sense of impending doom strongly supports a diagnosis of ACS.9  
* **Atypical and Anginal Equivalent Presentations:** It is a clinical imperative to recognize that a significant portion of patients with STEMI do not present with chest pain. This is particularly true for older adults, women, and individuals with diabetes mellitus.1 These patients may present with "anginal equivalents" such as isolated or predominant dyspnea, epigastric pain (often mistaken for indigestion), unexplained weakness, or altered mental status.13 Women are more likely than men to present with accompanying symptoms like nausea, shortness of breath, and pain in the back or jaw.12 The 2021 AHA/ACC Chest Pain Guideline emphasizes that pain, pressure, or discomfort in the chest, shoulders, arms, neck, back, upper abdomen, or jaw, as well as shortness of breath and fatigue, should all be considered potential anginal equivalents.18 The guideline also discourages the use of the term "atypical chest pain" as it is misleading and may prematurely lower the suspicion for ACS; the term "noncardiac" is preferred if an alternative diagnosis is certain.18 The over-reliance on a "typical" presentation can lead to critical delays in diagnosis and treatment. The diagnostic approach must therefore be broad, maintaining a high index of suspicion for any new, unexplained, and concerning symptoms in patients with risk factors for cardiovascular disease.

##### **Cardiovascular Risk Factors**

A systematic review of cardiovascular risk factors helps to establish the patient's baseline risk and pre-test probability for CAD.1

* **Non-Modifiable Risk Factors:**  
  * Age (risk increases with age) 2  
  * Male sex 9  
  * Family history of premature coronary artery disease (CAD) (e.g., first-degree male relative \<55 years or female relative \<65 years) 2  
* **Modifiable Risk Factors:**  
  * Tobacco use (current or recent smoker) 2  
  * Hypertension 2  
  * Dyslipidemia (elevated LDL-C, low HDL-C) 2  
  * Diabetes mellitus 2  
  * Abdominal obesity 2  
  * Sedentary lifestyle and physical inactivity 2  
  * Psychosocial stressors 2  
* **Other Significant Risk Factors:**  
  * Cocaine or other sympathomimetic drug use (can cause vasospasm-induced STEMI) 2  
  * Chronic kidney disease 9  
  * Known familial hypercholesterolemia 2

##### **Pertinent Medical and Surgical History**

* History of established cardiovascular disease: Prior MI, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or known angina.9  
* History of other atherosclerotic disease: Heart failure, stroke or transient ischemic attack (TIA), or peripheral vascular disease.11

#### **B. Physical Examination**

The physical examination should be performed concurrently with initial stabilization efforts and EKG acquisition. It is aimed at assessing hemodynamic stability, identifying signs of heart failure or mechanical complications, and uncovering clues to alternative diagnoses.

* **Initial Assessment (ABCDE Approach):** A rapid assessment of Airway, Breathing, and Circulation is the immediate priority to identify and manage any life-threatening instability.13  
* **Vital Signs:**  
  * **Blood Pressure:** May be elevated due to pain and sympathetic activation, or low (hypotension) in the setting of cardiogenic shock or right ventricular (RV) infarction.9 A critical step is to measure blood pressure in both arms; a difference in systolic pressure \>20 mmHg is highly suspicious for aortic dissection.2  
  * **Heart Rate:** Tachycardia may reflect sympathetic drive, pain, or heart failure. Bradycardia can occur, especially in inferior MI due to increased vagal tone or ischemia of the sinoatrial or atrioventricular nodes.9  
  * **Respiratory Rate:** Tachypnea can be a sign of anxiety, pain, or developing pulmonary edema.9  
  * **Temperature:** A low-grade fever may be present as part of the systemic inflammatory response to myocardial necrosis.9  
* **General Appearance:** Note the patient's level of distress. Anxious appearance and pale, cool, diaphoretic (clammy) skin are classic signs of sympathetic activation and hypoperfusion.9 The Levine's sign—a clenched fist held over the sternum—is a classic, though not universally present, sign of severe angina.13  
* **Cardiovascular Examination:**  
  * **Auscultation:** The cardiac exam can be normal. However, new findings are significant. Listen for an S3 gallop, which indicates left ventricular dysfunction and elevated filling pressures, or an S4 gallop, indicating a stiff, non-compliant ventricle.11 A new, harsh, holosystolic murmur may signify a life-threatening mechanical complication, such as acute mitral regurgitation due to papillary muscle rupture (murmur loudest at the apex) or a ventricular septal rupture (murmur loudest at the left sternal border).9 A pericardial friction rub (a high-pitched, scratching sound) may be heard in pericarditis but can also develop days after an MI (Dressler's syndrome).9  
  * **Jugular Venous Pressure (JVP):** An elevated JVP suggests elevated right-sided filling pressures, which may be due to RV infarction or biventricular failure.9  
* **Pulmonary Examination:** Auscultate the lung fields for bibasilar crackles (rales), which are a sign of pulmonary edema resulting from left ventricular failure.9  
* **Extremities:** Examine for peripheral edema, which can be a sign of chronic or acute-on-chronic heart failure. Assess all major pulses (radial, brachial, femoral, pedal) for presence, rate, and symmetry. Diminished or asymmetric pulses are another warning sign for aortic dissection or severe peripheral vascular disease.2

#### **C. Electrocardiogram (EKG) Interpretation**

The 12-lead EKG is the single most important diagnostic tool in the initial evaluation of a patient with suspected STEMI. It must be acquired and interpreted by an experienced clinician within 10 minutes of first medical contact.9 The diagnosis of STEMI is primarily an EKG-based diagnosis that triggers the entire reperfusion cascade; it should not be delayed by waiting for cardiac biomarker results.9

##### **Standard STEMI Criteria**

The diagnosis is made based on new ST-segment elevation at the J-point in at least two anatomically contiguous leads.13 The amplitude thresholds are specific to lead location and patient demographics:

* **Leads V2-V3:**  
  * ≥2.5 mm in men younger than 40 years 9  
  * ≥2 mm in men 40 years or older 9  
  * ≥1.5 mm in women (regardless of age) 9  
* **All Other Leads (Limb leads and V1, V4-V6):**  
  * ≥1 mm in both men and women 13

##### **Anatomic Localization and Culprit Artery Correlation**

The pattern of ST elevation provides a roadmap to the location of the myocardial injury and the likely occluded coronary artery.

* **Anterior STEMI (Leads V1-V4):** Indicates occlusion of the Left Anterior Descending (LAD) artery.9 Extensive anterior wall MIs (e.g., V1-V6, I, aVL) are associated with large areas of myocardial damage and a higher risk of complications.  
* **Inferior STEMI (Leads II, III, aVF):** Indicates occlusion of the Right Coronary Artery (RCA) in approximately 70-80% of cases or the Left Circumflex (LCX) artery.9  
* **Lateral STEMI (Leads I, aVL, V5-V6):** Indicates occlusion of the LCX or a diagonal branch of the LAD.9  
* **Right Ventricular (RV) Infarction:** Should be suspected in all patients with an inferior STEMI. Clues on the standard 12-lead EKG include ST elevation in V1 and ST elevation in lead III that is greater than the ST elevation in lead II. The diagnosis can be confirmed by obtaining right-sided precordial leads (V3R, V4R), which will show ST elevation.13 This diagnosis is critical as these patients are highly preload-dependent, and nitrates or other vasodilators can cause profound hypotension.

##### **Key Interpretive EKG Features**

* **Reciprocal Changes:** ST-segment depression in leads that are electrically opposite to the leads with ST elevation is a highly specific sign of acute MI. For example, an inferior STEMI (STE in II, III, aVF) will often show reciprocal ST depression in leads I and aVL.1 The presence of reciprocal changes greatly increases the certainty of the diagnosis, but their absence does not rule it out.  
* **ST-Segment Morphology:** The shape of the ST segment can be a clue. A convex upward ("tombstone") or straight, upsloping ST segment is highly characteristic of STEMI. A concave morphology ("happy face") is more often associated with pericarditis but can be seen in the very early stages of a STEMI.13  
* **Evolution of EKG Changes:** The EKG in STEMI is a dynamic process. The typical evolution is: 1\) Hyperacute T-waves (tall, broad-based T-waves) appear within minutes; 2\) ST-segment elevation follows; 3\) Pathologic Q-waves (indicating necrosis) develop over hours to days; and 4\) T-waves invert. If the initial EKG is non-diagnostic but clinical suspicion is high, serial EKGs every 15-30 minutes are essential.13

##### **STEMI Equivalents: Recognizing Occlusion MI Without Classic ST Elevation**

A critical skill is the recognition of EKG patterns that signify acute coronary occlusion but do not meet formal STEMI criteria. These "STEMI equivalents" require the same emergent reperfusion therapy.

* **Posterior Wall MI:** An isolated posterior MI results from occlusion of the LCX or posterior descending artery. It does not produce ST elevation on a standard 12-lead EKG. Instead, it creates reciprocal changes in the anterior leads: ST depression in leads V1-V3, often with prominent R waves (R/S ratio \>1 in V2) and upright T waves.1 The diagnosis is confirmed by obtaining posterior leads (V7-V9), which will show ST elevation ≥0.5 mm.13  
* **New or Presumed New Left Bundle Branch Block (LBBB):** For years, a new LBBB in the context of ischemic symptoms was considered a STEMI equivalent. This is no longer the case, as many patients with a new LBBB do not have an occlusion.1 However, identifying an occlusion MI in the setting of an LBBB (or a ventricular paced rhythm) is a major diagnostic challenge. The  
  **Sgarbossa Criteria** (and the more sensitive modified Sgarbossa criteria) are used to detect MI in this context 9:  
  * **Concordant ST elevation ≥1 mm** in a lead with a positive QRS complex (Score: 5\)  
  * **Concordant ST depression ≥1 mm** in any lead from V1-V3 (Score: 3\)  
  * **Excessively discordant ST elevation ≥5 mm** in a lead with a negative QRS complex (Score: 2\)  
  * A total score of ≥3 is highly specific for an acute MI and warrants emergent reperfusion.  
* **De Winter's T-Waves:** This pattern consists of upsloping ST-segment depression \>1 mm at the J-point in the precordial leads, followed by tall, prominent, symmetrical T-waves.13 There is typically no ST elevation in the precordial leads, but there may be mild ST elevation in lead aVR. This pattern is a high-risk sign of acute proximal LAD occlusion and must be treated as a STEMI equivalent.13  
* **Isolated ST Elevation in Lead aVR:** When seen with widespread ST depression in other leads (e.g., I, II, V4-V6), this pattern can indicate severe ischemia from a left main coronary artery occlusion or severe triple-vessel disease.1 These patients are at extremely high risk and require emergent angiography.

#### **D. Differential Diagnosis of ST-Segment Elevation**

Not all ST elevation is a STEMI. Misdiagnosis can lead to the inappropriate and potentially lethal administration of antithrombotic therapies (e.g., giving fibrinolytics to a patient with aortic dissection) or the unnecessary activation of the cardiac catheterization laboratory, which consumes resources and exposes the patient to procedural risk.10 A systematic approach to the differential diagnosis is therefore a critical component of the initial evaluation.9

##### **Table 1: Differential Diagnosis of ST-Segment Elevation**

| Feature | STEMI | Acute Pericarditis | Aortic Dissection | Pulmonary Embolism (PE) | Takotsubo Cardiomyopathy |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **Clinical: Pain** | Crushing, pressure, squeezing; radiates to arm/jaw; \>20 mins 12 | Sharp, pleuritic; worse supine, better sitting up 10 | Sudden, "tearing/ripping"; maximal at onset; may migrate to back 14 | Pleuritic, sudden onset; often with dyspnea 10 | Ischemic-type chest pain, often preceded by severe emotional/physical stress 25 |
| **Clinical: Other** | Diaphoresis, nausea, dyspnea 9 | Friction rub, fever 10 | Pulse/BP differential, new aortic regurgitation murmur, neuro deficits 27 | Hypoxia, tachycardia, syncope, signs of DVT 10 | Predominantly post-menopausal women 25 |
| **EKG: ST Elevation** | Localized (anterior, inferior, lateral); Convex/straight morphology 13 | Diffuse, widespread; Concave morphology 30 | Can cause true STEMI (often inferior) if coronary ostia are involved 15 | Can mimic anterior or inferior STEMI (RV strain/injury pattern) 33 | Often anterior (V2-V6), can be widespread; no reciprocal changes 35 |
| **EKG: Key Differentiators** | **Reciprocal ST depression**; Q-waves develop; STE in III \> II (inferior) 1 | **No reciprocal ST depression** (except aVR/V1); **widespread PR depression**; Spodick's sign 30 | EKG can be normal or non-specific; widened mediastinum on CXR is key 15 | S1Q3T3 pattern; RBBB; sinus tachycardia; T-wave inversions V1-V4 10 | **No reciprocal ST depression**; deep, widespread T-wave inversions; QT prolongation 35 |
| **Key Tests** | **hs-cTn** markedly elevated; **Angiography** shows occluded artery 39 | **hs-cTn** normal or mildly elevated; **Echo** may show pericardial effusion 10 | **D-Dimer** often elevated; **CT Angiogram or TEE** is diagnostic 22 | **D-Dimer** often elevated; **CT Angiogram** is diagnostic 10 | **hs-cTn** mildly elevated; **Angiography** shows normal coronaries; **Echo/Ventriculogram** shows apical ballooning 25 |

##### **Detailed Descriptions of Key STEMI Mimics**

* **Acute Pericarditis:** This is the most common condition that mimics STEMI. The inflammation of the pericardium causes repolarization abnormalities. Key differentiating features include the pain, which is typically sharp, pleuritic, and improves when sitting forward.10 The EKG shows diffuse, concave ST elevation in most leads, without the anatomically localized pattern of STEMI.30 Crucially, there are no true reciprocal ST depressions (except in aVR and V1).32 The presence of widespread PR segment depression is highly suggestive of pericarditis.30 A finding that strongly favors STEMI over pericarditis is ST elevation in lead III being greater than in lead II.37  
* **Benign Early Repolarization (BER):** This is a normal EKG variant, most commonly seen in young, healthy, asymptomatic individuals, particularly athletic males.21 The EKG shows concave ST elevation, usually most prominent in the precordial leads (V2-V5).10 A characteristic feature is a notched or slurred J-point, sometimes described as a "fish hook" pattern, especially in lead V4.10 The T-waves are typically prominent and the EKG pattern is stable over time, unlike the dynamic changes seen in STEMI.10  
* **Left Ventricular Hypertrophy (LVH):** Increased left ventricular muscle mass, typically from chronic hypertension or aortic stenosis, causes high QRS voltage and secondary repolarization abnormalities that can mimic an anterior STEMI.10 The EKG shows ST elevation in the right precordial leads (V1-V3), which are discordant to the deep S-waves in those leads. This is typically accompanied by ST depression and T-wave inversion (a "strain" pattern) in the lateral leads (I, aVL, V5-V6).10  
* **Takotsubo (Stress) Cardiomyopathy:** Also known as "broken heart syndrome," this condition is characterized by transient left ventricular dysfunction, often triggered by intense emotional or physical stress, and predominantly affects post-menopausal women.25 Patients present with chest pain, EKG changes, and elevated troponins, making it clinically indistinguishable from ACS initially.25 The EKG often shows ST elevation, typically in the anterior precordial leads, but usually lacks reciprocal changes.35 This is followed by the development of deep, diffuse T-wave inversions and marked QT interval prolongation.35 The definitive diagnosis is made at angiography, which reveals non-obstructed coronary arteries, and ventriculography or echocardiography, which shows the characteristic transient apical ballooning of the left ventricle that resembles a Japanese octopus trap ("takotsubo").26  
* **Aortic Dissection:** This is the most feared STEMI mimic. An intimal tear in the aorta allows blood to enter the vessel wall, creating a false lumen. If the dissection flap extends proximally to involve the coronary ostia, it can cause a true coronary occlusion and STEMI.15 The right coronary artery is most commonly affected, leading to an inferior STEMI.15 Clinical red flags are a sudden, severe, "tearing" pain that may radiate to the back, a significant blood pressure differential between the arms, a new murmur of aortic regurgitation, or focal neurologic deficits.27 The chest X-ray may show a widened mediastinum.27 Administering antiplatelet and anticoagulant therapy in this setting can be catastrophic, leading to uncontrolled hemorrhage.22 Diagnosis is confirmed with a CT angiogram or transesophageal echocardiogram (TEE).41  
* **Pulmonary Embolism (PE):** A massive PE can cause acute right heart strain and pressure overload, leading to myocardial ischemia and EKG changes that mimic an MI.29 Patients typically present with dyspnea, pleuritic chest pain, and hypoxia.10 The EKG may show sinus tachycardia (the most common finding), a new right bundle branch block, T-wave inversions in the anterior leads (V1-V4), or the classic (but insensitive) S1Q3T3 pattern.10 ST elevation can occur in the inferior or anterior leads, mimicking STEMI.33 Bedside echocardiography showing a dilated, hypokinetic right ventricle with a hyperdynamic apex (McConnell's sign) is a strong clue.29 The diagnosis is confirmed with a CT pulmonary angiogram.33

---

### **Section II: Confirmatory Diagnostic Workup**

While the initial reperfusion decision is based on the EKG and clinical presentation, subsequent diagnostic tests are crucial to confirm myocardial necrosis, quantify the extent of damage, assess cardiac function, and guide further management.

#### **A. Laboratory Studies**

##### **Cardiac Troponins (cTn)**

* **Role and Interpretation:** Cardiac troponins (cTnI and cTnT) are highly specific and sensitive biomarkers of myocardial cell injury.39 Their release into the bloodstream confirms the diagnosis of myocardial infarction.2 However, it is a critical point of practice that reperfusion therapy for STEMI is initiated based on EKG findings and should  
  **never** be delayed while awaiting troponin results.9 Troponins will initially be negative in the very early hours of a STEMI.  
* **High-Sensitivity Cardiac Troponins (hs-cTn):** These assays are now the standard of care in most institutions.43 They can detect very low levels of troponin, allowing for much earlier identification of myocardial injury compared to older, conventional assays.43  
* **Kinetics and Infarct Size:** Cardiac troponins begin to rise within 2 to 3 hours after the onset of myocardial injury, reach a peak concentration between 12 and 48 hours, and can remain elevated for 5 to 14 days.9 The magnitude of the peak troponin level and the area under the troponin-time curve correlate with the size of the myocardial infarction.39  
* **The Challenge of High Sensitivity:** The advent of hs-cTn assays has significantly improved the diagnosis of NSTEMI, but it has also introduced a new clinical challenge. These assays are so sensitive that they detect minor degrees of myocardial injury from a wide variety of cardiac and non-cardiac conditions, leading to a marked increase in the number of patients with an "elevated troponin".39 This underscores the critical distinction between  
  *myocardial injury* (any condition causing troponin release) and *myocardial infarction* (myocardial injury due to an acute ischemic mechanism). Conditions such as acute heart failure, myocarditis, pulmonary embolism, sepsis, chronic kidney disease, and strenuous exercise can all cause elevated troponin levels.9 This reality has shifted the diagnostic paradigm. The clinician's task is no longer simply to determine if the troponin is positive, but to interpret the  
  *pattern* of the troponin rise and fall (the delta) in the context of the patient's entire clinical picture (history, EKG, imaging). A significant rise and/or fall is the hallmark of an acute event like an MI, whereas a chronically elevated, stable troponin level is more suggestive of a chronic structural heart disease or renal failure. This differentiation is essential for directing appropriate therapy, as management for a Type 1 MI (atherothrombotic plaque rupture) is emergent revascularization, whereas management for Type 2 MI (supply-demand mismatch) or other causes of myocardial injury involves treating the underlying condition.2

##### **Other Essential Laboratory Investigations**

* **Complete Blood Count (CBC):** To assess for anemia, which can exacerbate myocardial ischemia, or thrombocytopenia, which increases bleeding risk with antiplatelet therapy. An elevated white blood cell count is a common non-specific finding.9  
* **Basic Metabolic Panel (BMP) / Urea & Electrolytes:** Essential for assessing renal function (creatinine, eGFR), which is critical for dosing of many cardiovascular medications (e.g., ACE inhibitors, certain anticoagulants) and for assessing the risk of contrast-induced nephropathy during angiography.9 It also screens for electrolyte abnormalities, such as hyperkalemia, which can be a STEMI mimic.10  
* **Lipid Profile:** A fasting lipid panel should be obtained, ideally within the first 24 hours of admission, to establish a baseline for initiating and titrating high-intensity statin therapy for secondary prevention.9  
* **Glucose and Hemoglobin A1c (HbA1c):** To screen for undiagnosed diabetes mellitus and to assess glycemic control in known diabetics. Stress hyperglycemia is common in ACS and is associated with worse clinical outcomes.9  
* **Coagulation Studies (PT/INR, aPTT):** To establish a baseline prior to the administration of anticoagulant therapies like heparin or bivalirudin.

#### **B. Imaging Studies**

##### **Chest X-Ray (CXR)**

A portable, anteroposterior chest X-ray should be obtained in the emergency department, but its performance must not delay the patient's transfer to the catheterization laboratory for reperfusion.46 The primary roles of the CXR are:

* **To exclude other life-threatening causes of chest pain**, such as tension pneumothorax or pneumonia.9  
* **To look for signs of aortic dissection**, specifically a widened mediastinum or abnormal aortic contour.13  
* **To assess for signs of heart failure**, which has significant prognostic implications. Findings include cardiomegaly (enlarged cardiac silhouette), cephalization of pulmonary vessels (vascular redistribution), Kerley B lines (interstitial edema), and frank alveolar edema or pleural effusions.9

##### **Transthoracic Echocardiography (TTE)**

An echocardiogram, whether a focused point-of-care ultrasound (POCUS) exam in the emergency department or a formal study, provides invaluable information in the acute setting.46

* **Confirming Ischemia:** The hallmark finding is a regional wall motion abnormality (RWMA)—such as hypokinesis, akinesis, or dyskinesis—in a pattern that corresponds to the territory of the occluded coronary artery suggested by the EKG.40 This finding greatly increases diagnostic certainty.  
* **Assessing Global Function:** The TTE provides a rapid assessment of global left ventricular systolic function, most commonly quantified by the Left Ventricular Ejection Fraction (LVEF), and can also calculate a Wall Motion Score Index (WMSI).50 A reduced LVEF (especially LVEF \<40%) identifies a patient at high risk for complications like heart failure and cardiogenic shock and has major implications for long-term therapy (e.g., need for ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists) and potential ICD placement.45  
* **Diagnosing Mechanical Complications:** Echocardiography is the primary tool for rapidly diagnosing life-threatening mechanical complications of STEMI, such as acute severe mitral regurgitation from papillary muscle rupture, ventricular septal rupture, or free wall rupture with pericardial effusion and tamponade.9  
* **Aiding in Differential Diagnosis:** TTE can reveal key features of STEMI mimics, including a pericardial effusion in pericarditis, right ventricular dilation and dysfunction in pulmonary embolism, the characteristic apical ballooning of Takotsubo cardiomyopathy, or an intimal flap in the aortic root in aortic dissection.26

##### **Coronary Angiography**

This is the definitive diagnostic test for STEMI. It is performed emergently as part of the primary PCI strategy. It provides direct visualization of the coronary anatomy, identifies the site of the thrombotic occlusion (the "culprit lesion"), and assesses the severity and extent of underlying coronary artery disease in other vessels.40 This is a combined diagnostic and therapeutic procedure.

##### **Advanced Imaging (Cardiac CT/MRI)**

These modalities are generally not used in the initial, time-sensitive diagnosis of STEMI. However, they have important roles in specific circumstances.46

* **Cardiac Computed Tomography (CT):** A cardiac CT angiogram is the test of choice for ruling out aortic dissection or pulmonary embolism when these are strong clinical possibilities.33  
* **Cardiac Magnetic Resonance (CMR):** CMR is the gold standard for assessing myocardial viability, quantifying infarct size, and detecting microvascular obstruction. It is particularly valuable in the workup of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) to differentiate among causes like myocarditis, small vessel disease, or resolved thrombus.31

---

### **Section III: Acute Management and Reperfusion**

The management of STEMI is centered on the immediate restoration of blood flow to the ischemic myocardium. This is achieved through a combination of prompt pharmacotherapy and an organized reperfusion strategy.

#### **A. Immediate Medical Therapy**

Upon diagnosis of STEMI, a standard set of medications should be administered immediately, unless contraindicated, to reduce pain, limit infarct size, and prevent thrombotic complications. While the mnemonic "MONA" (Morphine, Oxygen, Nitrates, Aspirin) is historically taught, its application has been refined by modern evidence.

##### **Table 2: Acute STEMI Pharmacotherapy**

| Drug Class | Agent(s) | Loading Dose | Key Indications & Notes | Guideline Source(s) |
| :---- | :---- | :---- | :---- | :---- |
| **Antiplatelet** | Aspirin | 162-325 mg (non-enteric coated, chewable) | **Class I:** Give to all patients without contraindications immediately. Chewing enhances rapid absorption. | 20 |
| **P2Y12 Inhibitor** | Ticagrelor | 180 mg | **Preferred** over clopidogrel for most patients undergoing PPCI due to faster onset and greater potency. | 45 |
|  | Prasugrel | 60 mg | **Preferred** over clopidogrel for PPCI. **Contraindicated** in patients with a history of stroke or TIA. Use with caution in age \>75 or body weight \<60 kg. | 45 |
|  | Clopidogrel | 300-600 mg | Used when ticagrelor/prasugrel are contraindicated or unavailable. It is the P2Y12 inhibitor of choice for patients receiving fibrinolytic therapy. | 20 |
| **Anticoagulant** | Unfractionated Heparin (UFH) | 60 U/kg IV bolus (max 4000 U), then 12 U/kg/hr infusion (max 1000 U/hr) | Standard of care anticoagulant to support PPCI. | 20 |
|  | Enoxaparin (LMWH) | 1 mg/kg SC q12h (or IV bolus \+ SC dose with fibrinolysis) | An alternative to UFH for PPCI. The preferred anticoagulant for patients receiving fibrinolysis. | 20 |
| **Statin** | Atorvastatin | 80 mg | **High-intensity statin** therapy should be initiated as early as possible, regardless of baseline cholesterol levels, for its pleiotropic anti-inflammatory and plaque-stabilizing effects. | 45 |
|  | Rosuvastatin | 20-40 mg | An alternative high-intensity statin. | 57 |
| **Analgesia** | Nitroglycerin | 0.4 mg sublingual every 5 minutes for up to 3 doses | For active ischemic chest pain. Causes vasodilation. **Contraindicated** in hypotension (SBP \<90 mmHg), severe bradycardia, or suspected RV infarction. | 9 |
|  | Morphine | 2-4 mg IV every 5-15 minutes as needed | For chest pain refractory to nitrates. Use with caution, as it can cause hypotension, respiratory depression, and may delay the absorption and action of oral P2Y12 inhibitors. | 9 |
| **Beta-Blocker** | Metoprolol | 25-50 mg PO q6-12h (or 5 mg IV x3 doses q5min) | An oral beta-blocker should be initiated within the first 24 hours in patients who are hemodynamically stable and do not have signs of heart failure, a low-output state, or other contraindications. IV beta-blockers may be considered in hypertensive patients without signs of HF. | 20 |
| **Oxygen** | \- | 2-4 L via nasal cannula | **Only for patients with documented hypoxemia (arterial oxygen saturation SaO2​ \< 90%)**. Routine administration of supplemental oxygen to normoxic patients is not recommended and may be harmful due to coronary vasoconstriction. | 9 |

#### **B. Reperfusion Strategy**

The primary goal of STEMI care is rapid, complete, and sustained reperfusion of the infarct-related artery. The choice between primary PCI and fibrinolytic therapy depends entirely on anticipated time to treatment.

##### **Primary Percutaneous Coronary Intervention (PPCI)**

PPCI is the gold standard and the preferred reperfusion strategy when it can be performed by an experienced team in a timely manner.1 It is superior to fibrinolysis in achieving vessel patency and is associated with lower rates of death, recurrent MI, and intracranial hemorrhage.

* **Time Goals:** The establishment of regional STEMI systems of care is designed to minimize total ischemic time. Key time-to-treatment metrics are:  
  * **First Medical Contact (FMC)-to-Device Time:** For patients presenting to a PCI-capable hospital, the goal is ≤90 minutes.20  
  * **FMC-to-Device Time (Transfer):** For patients who must be transferred from a non-PCI-capable hospital, the total time from FMC to device activation should be ≤120 minutes.9 If this timeline cannot be met, fibrinolysis should be considered.  
* **Indications:**  
  * **Class I:** Recommended for patients with symptom onset within the previous 12 hours.57  
  * **Class I:** Indicated for patients with cardiogenic shock or acute severe heart failure, irrespective of the time delay from symptom onset.56  
  * **Class IIa (Reasonable):** For patients presenting between 12 and 24 hours after symptom onset who have evidence of ongoing ischemia, hemodynamic instability, or life-threatening arrhythmias.56  
  * **Class III (No Benefit/Harm):** Should not be performed in stable, asymptomatic patients with a totally occluded infarct artery \>24 hours after symptom onset.57  
* **Procedural Considerations and Guideline Updates:**  
  * **Vascular Access:** There has been a definitive shift in practice towards transradial access. The 2025 ACC/AHA guidelines give a Class I recommendation for using a **radial artery approach** over a femoral approach for ACS patients undergoing PCI. This is based on robust evidence showing significant reductions in bleeding, vascular complications, and even mortality with the radial approach.57  
  * **Complete Revascularization:** For STEMI patients found to have multivessel CAD, a strategy of **complete revascularization** (PCI of significant non-culprit lesions) is now a Class I recommendation. This is based on trials like COMPLETE, which showed this approach reduces the risk of cardiovascular death or recurrent MI compared to a culprit-lesion-only strategy.61 This can be performed either during the index procedure or as a planned, staged procedure within 45 days.20 This recommendation does  
    **not** apply to patients presenting in cardiogenic shock, where the CULPRIT-SHOCK trial supports an initial culprit-lesion-only strategy to minimize procedural time and risk.63  
  * **Intracoronary Imaging:** The use of intravascular imaging, such as Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT), has been elevated to a Class I recommendation in the 2025 ACC/AHA guidelines for guiding PCI in patients with complex disease.57 Imaging helps optimize stent sizing, ensure adequate stent expansion, and identify edge dissections, leading to improved long-term outcomes.

##### **Fibrinolysis (Thrombolytic Therapy)**

Fibrinolysis is a valuable reperfusion strategy but is reserved for settings where timely PPCI is unavailable.9

* **Indications:** Fibrinolytic therapy should be administered to STEMI patients with symptom onset ≤12 hours if the anticipated delay to PPCI from FMC is \>120 minutes.20  
* **Time Goal:** The goal is to administer the fibrinolytic agent within 10 minutes of the STEMI diagnosis (often referred to as "door-to-needle" time).20 Pre-hospital fibrinolysis by trained EMS personnel is recommended to shorten ischemic time.20  
* **Pharmaco-invasive Strategy:** This is the modern approach to fibrinolysis. After the lytic agent is administered, **all patients** should be immediately transferred to a PCI-capable center.20  
  * **Successful Lysis:** For patients with successful reperfusion (e.g., \>50% ST-segment resolution), routine angiography with intent to perform PCI should be done between 2 and 24 hours later.20  
  * **Failed Lysis:** For patients with evidence of failed reperfusion (persistent chest pain, minimal ST resolution), immediate **rescue PCI** is indicated.20  
* **Contraindications:** Fibrinolysis carries a significant risk of bleeding, particularly intracranial hemorrhage. A careful screening for contraindications is mandatory before administration.

##### **Table 3: Absolute Contraindications to Fibrinolytic Therapy**

| Contraindication |
| :---- |
| Any prior intracranial hemorrhage |
| Known structural cerebral vascular lesion (e.g., arteriovenous malformation) |
| Known malignant intracranial neoplasm (primary or metastatic) |
| Ischemic stroke within the last 3 months |
| Suspected aortic dissection |
| Active bleeding or bleeding diathesis (excluding menses) |
| Significant closed-head trauma or facial trauma within the last 3 months |
| Intracranial or intraspinal surgery within the last 2 months |
| Severe uncontrolled hypertension (systolic BP \>180 mmHg or diastolic BP \>110 mmHg) unresponsive to emergency therapy |

---

### **Section IV: Management of In-Hospital Complications**

Despite optimal reperfusion, STEMI can be complicated by life-threatening conditions that require intensive management.

#### **A. Cardiogenic Shock (CS)**

Cardiogenic shock is the most severe complication of STEMI, characterized by a state of low cardiac output and end-organ hypoperfusion due to severe left (and sometimes right) ventricular dysfunction. It carries a mortality rate of 40-50%.60

* **Definition:** The clinical diagnosis is based on 64:  
  * **Persistent Hypotension:** Systolic blood pressure (SBP) \<90 mmHg for \>30 minutes, or the need for vasopressor support to maintain SBP ≥90 mmHg.  
  * **Evidence of End-Organ Hypoperfusion:** Cool, clammy extremities; altered mental status; oliguria (urine output \<30 mL/hr); or elevated serum lactate (\>2.0 mmol/L).  
  * **Pulmonary Congestion:** Often present, indicating elevated left ventricular filling pressures.  
* **Initial Management:** Management is a race against time to reverse the shock state and prevent irreversible organ damage.  
  * **Airway and Breathing:** Many patients require respiratory support. Non-invasive positive pressure ventilation (e.g., CPAP) can decrease the work of breathing, improve oxygenation, and reduce both preload and afterload. Intubation and mechanical ventilation are often necessary for airway protection and to fully control respiratory mechanics.13  
  * **Hemodynamic Support:** The goal is to restore a mean arterial pressure sufficient for organ perfusion (typically \>65 mmHg) without excessively increasing cardiac workload.  
    * **Vasopressors:** **Norepinephrine** is the first-line agent. Its potent alpha-1 adrenergic effects increase systemic vascular resistance and blood pressure, while its beta-1 effects provide modest inotropic support.66 It is preferred over dopamine, which was associated with more arrhythmias and higher mortality in a trial of cardiogenic shock patients.66  
    * **Inotropes:** If signs of low cardiac output persist despite adequate blood pressure, an inotrope such as **dobutamine** can be added to increase myocardial contractility and cardiac output.66  
  * **Emergent Reperfusion:** The single most effective therapy to improve survival in AMI-CS is **emergent revascularization** of the culprit coronary artery.55 As established by the CULPRIT-SHOCK trial, this should be an  
    **IRA-only PCI** strategy in the acute setting to minimize procedural complexity and risk in these critically ill patients.63  
* **Mechanical Circulatory Support (MCS):**  
  * The management of AMI-CS has seen a significant evolution, moving from a reactive approach to a proactive, team-based model focused on early recognition and intervention. This shift is driven by the persistently high mortality rates and new evidence from clinical trials. The historical reliance on the intra-aortic balloon pump (IABP) was largely abandoned for routine use after the IABP-SHOCK II trial showed no mortality benefit.70 This created a therapeutic void and spurred interest in more potent temporary MCS devices. The concept of a multidisciplinary "Shock Team"—comprising interventional cardiologists, heart failure specialists, cardiac surgeons, and critical care physicians—has emerged as a best practice. This team-based approach facilitates rapid, standardized evaluation and decision-making, including the potential for transfer to a high-volume "hub" center with advanced MCS capabilities.68  
  * The recent DanGer Shock trial was a landmark study, being the first randomized trial to demonstrate a survival benefit for any MCS device in AMI-CS. It showed that early implantation of a **microaxial flow pump (Impella CP)** reduced 180-day mortality compared to standard care.69 However, this benefit came at the cost of significantly higher rates of bleeding and limb ischemia. This highlights the current paradigm: MCS is not a routine intervention but a selective therapy for patients with refractory shock, where the potential benefit of improved hemodynamics is carefully weighed against the procedural risks by an expert shock team. The SCAI shock classification (Stage A "At Risk" to Stage E "Extremis") provides a valuable framework for staging shock severity and guiding the escalation of therapy.70

#### **B. Arrhythmias**

Electrical instability is common in the setting of acute ischemia and necrosis.

* **Ventricular Arrhythmias (Ventricular Tachycardia/Fibrillation \- VT/VF):**  
  * **Incidence and Management:** Malignant ventricular arrhythmias are a major cause of death, especially in the pre-hospital setting. They are most common in the first few hours of STEMI.71 Management consists of immediate defibrillation/cardioversion according to ACLS protocols. The most important antiarrhythmic therapies are prompt reperfusion to correct ischemia and correction of electrolyte abnormalities (especially hypokalemia and hypomagnesemia). Intravenous amiodarone or lidocaine can be used for recurrent or refractory VT/VF.72  
  * **Prognostic Significance:** A distinction is made based on timing:  
    * **Early VAs (\<48 hours):** These are often triggered by acute ischemia and reperfusion. While they are associated with a higher in-hospital mortality, they do not independently predict an increased long-term risk of sudden cardiac death (SCD) if the patient survives the acute event.71  
    * **Late VAs (\>48 hours):** These arrhythmias are more likely to arise from a fixed scar substrate. They are a marker of significant myocardial damage and are associated with a poor long-term prognosis and a high risk of future SCD, often warranting consideration for an implantable cardioverter-defibrillator (ICD).71  
* **Atrial Fibrillation (AF):**  
  * **Management:** New-onset AF in the setting of STEMI is often a sign of atrial stretch due to high left ventricular filling pressures. Management focuses on controlling the ventricular rate, typically with intravenous beta-blockers or amiodarone (if heart failure is present).20 Electrical cardioversion is used for hemodynamically unstable patients.73 The decision for long-term anticoagulation is complex, requiring a careful balance of the patient's stroke risk (CHA₂DS₂-VASc score) against the high bleeding risk of triple therapy (aspirin \+ P2Y12 inhibitor \+ oral anticoagulant).20  
* **Bradyarrhythmias and AV Block:**  
  * **Incidence and Cause:** These are particularly common with inferior wall MI due to occlusion of the RCA, which supplies the AV node in most individuals. The resulting bradycardia and AV block are often transient and resolve with reperfusion.30  
  * **Management:** For hemodynamically significant bradycardia, intravenous atropine is the first-line treatment. If this is ineffective, temporary transcutaneous or transvenous pacing may be required.20 A permanent pacemaker is indicated if a high-degree (second-degree Mobitz II or third-degree) AV block persists for more than 5-7 days post-MI, as this suggests permanent damage to the conduction system.20

---

### **Section V: Discharge and Long-Term Follow-up**

The transition from inpatient to outpatient care is a critical period. The focus shifts to aggressive secondary prevention to reduce the high risk of recurrent ischemic events, heart failure, and death.

#### **A. Secondary Prevention Pharmacotherapy**

Adherence to guideline-directed medical therapy (GDMT) is the cornerstone of long-term management and has been proven to save lives. Suboptimal adherence remains a major public health issue.76 Most patients should be discharged on a combination of at least four classes of medications.

##### **Table 4: Long-Term Secondary Prevention Medications Post-STEMI**

| Drug Class | Agent(s) | Indication | Goal/Duration | Guideline Source(s) |
| :---- | :---- | :---- | :---- | :---- |
| **Dual Antiplatelet Therapy (DAPT)** | Aspirin (75-100mg daily) \+ P2Y12 Inhibitor (Clopidogrel 75mg, Ticagrelor 90mg BID, or Prasugrel 10mg daily) | All post-STEMI patients without a contraindication. | **Lifelong** low-dose Aspirin. A P2Y12 inhibitor should be continued for at least **12 months** as the default strategy. The duration may be shortened (e.g., 3-6 months) for patients at high bleeding risk or extended beyond 12 months for those with high ischemic risk and low bleeding risk. | 20 |
| **High-Intensity Statin** | Atorvastatin 80mg, Rosuvastatin 20-40mg | All patients, regardless of baseline cholesterol levels. | **Lifelong**. The goal is an LDL-C reduction of ≥50% from baseline AND an absolute LDL-C level of **\<55 mg/dL (1.4 mmol/L)** per ESC guidelines or **\<70 mg/dL (1.8 mmol/L)** per ACC/AHA guidelines. | 20 |
| **Beta-Blocker** | Metoprolol succinate, Carvedilol, Bisoprolol | All patients without contraindications. | Should be continued for at least 12-36 months. Prescribed **lifelong** for patients with left ventricular systolic dysfunction (LVEF ≤40%) or heart failure. | 20 |
| **ACE Inhibitor or ARB** | Ramipril, Lisinopril, Valsartan, Candesartan | Indicated for all patients with LVEF ≤40%, hypertension, diabetes, or chronic kidney disease. Reasonable for all other post-MI patients. | **Lifelong**. Titrate to the maximum tolerated dose while monitoring blood pressure and renal function. | 20 |
| **Aldosterone Antagonist (MRA)** | Eplerenone, Spironolactone | Patients already on an ACEi and beta-blocker who have an LVEF ≤40% AND either symptomatic heart failure or diabetes mellitus. | **Lifelong**. Contraindicated in significant renal dysfunction or hyperkalemia. Renal function and potassium levels must be monitored closely. | 53 |
| **Other Therapies** | SGLT2 Inhibitors / GLP-1 Receptor Agonists | Should be considered for patients with established ASCVD and Type 2 Diabetes. | These agents have been shown to reduce Major Adverse Cardiovascular Events (MACE). | 57 |
|  | Icosapent ethyl | May be considered for patients with established ASCVD and elevated triglycerides (135-499 mg/dL) despite maximally tolerated statin therapy. | Reduces MACE. | 99 |
|  | Colchicine | Low-dose colchicine (0.5 mg daily) may be considered for additional secondary prevention in patients at high risk. | Reduces MACE. | 57 |

#### **B. Cardiac Rehabilitation and Lifestyle Modification**

Pharmacotherapy must be paired with comprehensive lifestyle changes, best delivered through a structured cardiac rehabilitation program.

* **Cardiac Rehabilitation (CR):** This is a Class I recommendation for all eligible post-MI patients.77 Despite overwhelming evidence demonstrating its benefits, CR remains profoundly underutilized. Studies consistently show that participation in CR reduces cardiovascular mortality by up to 26%, all-cause mortality, and hospital readmissions by over 30%, while improving functional capacity and quality of life.80 The low referral and participation rates, often below 30%, represent a major evidence-practice gap in modern cardiology.79 This systemic failure to deliver a proven, life-saving intervention has prompted the development of alternative models, such as home-based and virtual CR programs, to improve access and adherence.78  
* **Core Components of CR:** CR is a multidisciplinary program that includes 78:  
  * **Medically Supervised Exercise Training:** A personalized prescription of aerobic and resistance exercise.  
  * **Nutritional Counseling:** Guidance on a heart-healthy diet, such as the Mediterranean diet, which is rich in fruits, vegetables, and fish, and low in saturated fats.45  
  * **Comprehensive Risk Factor Management:** Active management of blood pressure, lipids, and diabetes.  
  * **Psychosocial Support:** Screening and management for stress, anxiety, and depression, which are common post-MI.  
  * **Patient Education:** Empowering patients with knowledge about their condition, medications, and warning signs of recurrence.  
* **Lifestyle Modification Goals:**  
  * **Smoking Cessation:** Complete and permanent cessation of all tobacco products is the single most important lifestyle intervention, associated with up to a 50% reduction in mortality.16  
  * **Physical Activity:** Patients should aim for 30-60 minutes of moderate-intensity aerobic activity (e.g., brisk walking) on at least 5, and preferably 7, days per week.80  
  * **Weight Management:** Maintain a healthy body weight with a target Body Mass Index (BMI) of 20-25 kg/m² and a healthy waist circumference.80

#### **C. Follow-up Plan**

A structured follow-up plan is essential to monitor recovery, titrate medications, and reinforce secondary prevention goals.

* **Initial Post-Discharge Follow-up:** An early follow-up visit, typically within 1-2 weeks of discharge, is crucial to assess the patient's clinical status, review medication tolerance and adherence, and answer questions.2  
* **Key Follow-up Assessments:**  
  * **Lipid Panel:** A fasting lipid panel should be rechecked 4 to 8 weeks after initiating or titrating statin therapy to ensure that LDL-C goals are being met. If not at goal, therapy should be intensified with the addition of a non-statin agent like ezetimibe or a PCSK9 inhibitor.45  
  * **Echocardiogram for LVEF Reassessment:** The LVEF can improve in the weeks following successful reperfusion. A repeat TTE is often performed 40 days to 3 months post-MI to obtain a stable assessment of ventricular function. This timing is critical because it has major implications for primary prevention of SCD. If the LVEF remains ≤35% despite at least 40 days of optimal medical therapy, the patient is a candidate for an implantable cardioverter-defibrillator (ICD).20  
  * **Psychosocial Assessment:** Ongoing screening for depression, anxiety, and sleep disorders should be part of routine follow-up, as these conditions are prevalent post-MI and can negatively impact recovery and adherence to therapy.77

---

### **Section VI: Key Guidelines and Literature**

The management of STEMI is a rapidly evolving field, guided by evidence from large clinical trials that are synthesized into clinical practice guidelines by major cardiovascular societies.

#### **A. Clinical Practice Guidelines**

The following documents represent the current standards of care for the management of STEMI.

* **2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes:** The most current and comprehensive American guideline, which consolidates recommendations for both STEMI and NSTE-ACS into a single document.57  
  * **Link:** [https://www.jacc.org/guidelines/acute-coronary-syndromes](https://www.jacc.org/guidelines/acute-coronary-syndromes)  
* **2023 ESC Guidelines for the management of acute coronary syndromes:** The most current European guideline, which similarly provides a unified approach to the entire spectrum of ACS.20  
  * **Link:** [https://academic.oup.com/eurheartj/article/44/38/3720/7243210](https://academic.oup.com/eurheartj/article/44/38/3720/7243210)  
* **2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization:** Provides in-depth recommendations on the technical aspects of PCI and CABG, including stent choice and management of multivessel disease.58  
  * **Link:** [https://www.jacc.org/doi/10.1016/j.jacc.2021.09.006](https://www.jacc.org/doi/10.1016/j.jacc.2021.09.006)  
* **2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain:** Informs the initial diagnostic approach, risk stratification, and the appropriate use of terminology for chest pain presentations.18  
  * **Link:**([https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029))

#### **B. Summary of Recent Guideline Updates (2023 ESC & 2025 ACC/AHA)**

Recent guidelines have introduced several practice-changing recommendations:

* **Dual Antiplatelet Therapy (DAPT):** There is a stronger preference for the more potent P2Y12 inhibitors, ticagrelor and prasugrel, over clopidogrel for most ACS patients undergoing PCI. The guidelines also provide more nuanced recommendations on DAPT duration, allowing for de-escalation strategies or shorter durations (e.g., 3-6 months) in patients with a high bleeding risk.20  
* **Lipid Management:** LDL-C goals have become more aggressive. The ESC recommends a target of \<55 mg/dL (\<1.4 mmol/L), while the ACC/AHA recommends \<70 mg/dL (\<1.8 mmol/L) with a goal of \<55 mg/dL being reasonable for very high-risk patients. There is a strong emphasis on early initiation of high-intensity statins and the prompt addition of non-statin therapies (e.g., ezetimibe, PCSK9 inhibitors) if goals are not achieved with statins alone.20  
* **Complete Revascularization:** A major paradigm shift is the strong recommendation (Class I) to perform complete revascularization (PCI of significant non-culprit lesions) in stable STEMI patients with multivessel disease. This can be done at the time of the index PCI or as a planned staged procedure and is proven to reduce future ischemic events.20  
* **PCI Technique:** Radial artery access is now the strongly preferred (Class I) default approach for coronary angiography and PCI in ACS, based on clear evidence of reduced bleeding and mortality.20  
* **Intracoronary Imaging:** The use of IVUS or OCT to guide and optimize complex PCI has been elevated to a strong (Class I in ACC/AHA 2025\) recommendation, as it has been shown to improve stent implantation and clinical outcomes.57  
* **Cardiogenic Shock:** Guidelines now explicitly recommend against the routine use of an IABP. Early revascularization of the culprit lesion only is the recommended strategy. The role of advanced MCS is evolving, with new trial data supporting selective use in specialized centers.57

#### **C. Annotated Bibliography of Seminal Literature**

* **SHOCK Trial (1999):** This landmark trial established that a strategy of early revascularization (with either PCI or CABG) resulted in significantly lower 6-month and 1-year mortality compared to initial medical stabilization for patients with acute MI complicated by cardiogenic shock. It remains the foundation of modern CS management.70  
* **PLATO Trial (2009) & TRITON-TIMI 38 Trial (2007):** These two pivotal trials established the superiority of the newer, more potent P2Y12 inhibitors. PLATO showed that ticagrelor was superior to clopidogrel in reducing a composite of vascular death, MI, or stroke in a broad population of ACS patients.96 TRITON-TIMI 38 demonstrated that prasugrel was more effective than clopidogrel in reducing ischemic events in patients with ACS undergoing PCI, albeit with an increased risk of bleeding.96  
* **CULPRIT-SHOCK Trial (2017):** This trial addressed the question of revascularization strategy in patients with AMI, multivessel disease, and cardiogenic shock. It found that an initial strategy of performing PCI on the culprit lesion only was superior to immediate multivessel PCI, resulting in a lower 30-day risk of the composite endpoint of death or renal replacement therapy. This established culprit-lesion-only PCI as the standard initial approach for this high-risk population.63  
* **COMPLETE Trial (2019):** This trial definitively answered the question of how to manage non-culprit lesions in stable STEMI patients with multivessel disease. It showed that a strategy of complete revascularization with staged PCI of all significant non-culprit lesions was superior to a culprit-lesion-only strategy, significantly reducing the long-term risk of cardiovascular death or new MI.61  
* **DanGer Shock Trial (2023):** This is the first randomized controlled trial to show a mortality benefit for any mechanical circulatory support device in AMI-cardiogenic shock. It found that early initiation of an Impella CP microaxial flow pump reduced all-cause mortality at 180 days compared to standard of care. However, this benefit was accompanied by higher rates of complications, including severe bleeding and limb ischemia, highlighting the need for careful patient selection by expert teams.69

#### **Works cited**

1. ST elevation myocardial infarction \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5922709/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5922709/)  
2. Acute ST-Segment Elevation Myocardial Infarction (STEMI) \- StatPearls \- NCBI Bookshelf, accessed June 28, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK532281/](https://www.ncbi.nlm.nih.gov/books/NBK532281/)  
3. OPQRST, accessed June 28, 2025, [https://pami.emergency.med.jax.ufl.edu/wordpress/files/2019/10/OPQRST.pdf](https://pami.emergency.med.jax.ufl.edu/wordpress/files/2019/10/OPQRST.pdf)  
4. Assess OPQRST symptoms \- FIREHOUSE Software by ESO, accessed June 28, 2025, [https://www.firehousesoftware.com/webhelp/FHMedic/Content/Windows/UsersGuide/27\_AssessOPQRSTSymptoms.htm](https://www.firehousesoftware.com/webhelp/FHMedic/Content/Windows/UsersGuide/27_AssessOPQRSTSymptoms.htm)  
5. OPQRST: a Paramedic's Number 1 Mnemonic \- Elite Ambulance, accessed June 28, 2025, [https://eliteamb.com/opqrst-a-paramedics-number-1-mnemonic/](https://eliteamb.com/opqrst-a-paramedics-number-1-mnemonic/)  
6. How to use OPQRST as an effective patient pain assessment tool, accessed June 28, 2025, [https://www.ems1.com/ems-products/education/articles/how-to-use-opqrst-as-an-effective-patient-assessment-tool-yd2KWgJIBdtd7D5T/](https://www.ems1.com/ems-products/education/articles/how-to-use-opqrst-as-an-effective-patient-assessment-tool-yd2KWgJIBdtd7D5T/)  
7. OPQRST \- Wikipedia, accessed June 28, 2025, [https://en.wikipedia.org/wiki/OPQRST](https://en.wikipedia.org/wiki/OPQRST)  
8. Medical Patient Assessment for Chest Pain (OPQRST) \- Appropedia, accessed June 28, 2025, [https://www.appropedia.org/Medical\_Patient\_Assessment\_for\_Chest\_Pain\_(OPQRST)](https://www.appropedia.org/Medical_Patient_Assessment_for_Chest_Pain_\(OPQRST\))  
9. ST-Elevation Myocardial Infarction (STEMI) | ACS Geeky Medics, accessed June 28, 2025, [https://geekymedics.com/st-elevation-myocardial-infarction-stemi/](https://geekymedics.com/st-elevation-myocardial-infarction-stemi/)  
10. STEMI Mimics: Spot Subtle Impostors of Myocardial Infarction, accessed June 28, 2025, [https://www.powerfulmedical.com/blog/stemi-mimics/](https://www.powerfulmedical.com/blog/stemi-mimics/)  
11. Utility of the History and Physical Examination in the Detection of Acute Coronary Syndromes in Emergency Department Patients \- PubMed Central, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5468083/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5468083/)  
12. STEMI heart attack: Symptoms and more \- MedicalNewsToday, accessed June 28, 2025, [https://www.medicalnewstoday.com/articles/stemi-heart-attack](https://www.medicalnewstoday.com/articles/stemi-heart-attack)  
13. STEMI \- Electrocardiogram \- M3 Curriculum \- SAEM, accessed June 28, 2025, [https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m3-curriculum/group-electrocardiogram-(ecg)-rhythm-recognition/stemi](https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m3-curriculum/group-electrocardiogram-\(ecg\)-rhythm-recognition/stemi)  
14. ST elevation myocardial infarction differential diagnosis \- wikidoc, accessed June 28, 2025, [https://www.wikidoc.org/index.php/ST\_elevation\_myocardial\_infarction\_differential\_diagnosis](https://www.wikidoc.org/index.php/ST_elevation_myocardial_infarction_differential_diagnosis)  
15. Acute Aortic Dissection • LITFL • CCC Cardiology, accessed June 28, 2025, [https://litfl.com/acute-aortic-dissection/](https://litfl.com/acute-aortic-dissection/)  
16. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update \- JACC Journals, accessed June 28, 2025, [https://www.jacc.org/doi/10.1016/j.jacc.2011.10.824](https://www.jacc.org/doi/10.1016/j.jacc.2011.10.824)  
17. What is a STEMI Heart Attack? \- Cleveland Clinic, accessed June 28, 2025, [https://my.clevelandclinic.org/health/diseases/22068-stemi-heart-attack](https://my.clevelandclinic.org/health/diseases/22068-stemi-heart-attack)  
18. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation, accessed June 28, 2025, [https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029)  
19. ST-elevation myocardial infarction \- Symptoms, diagnosis and treatment | BMJ Best Practice, accessed June 28, 2025, [https://bestpractice.bmj.com/topics/en-gb/3000103](https://bestpractice.bmj.com/topics/en-gb/3000103)  
20. 2023 ESC Guidelines for the management of ... \- Oxford Academic, accessed June 28, 2025, [https://academic.oup.com/eurheartj/article-pdf/44/38/3720/56728087/ehad191.pdf](https://academic.oup.com/eurheartj/article-pdf/44/38/3720/56728087/ehad191.pdf)  
21. ST-segment elevation: Differential diagnosis, caveats \- Cleveland Clinic Journal of Medicine, accessed June 28, 2025, [https://www.ccjm.org/content/ccjom/82/6/373.full.pdf](https://www.ccjm.org/content/ccjom/82/6/373.full.pdf)  
22. Type A Aortic Dissection Presenting with Inferior ST-Elevation Myocardial Infarction \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4804865/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4804865/)  
23. ST-segment elevation: Differential diagnosis, caveats | Cleveland Clinic Journal of Medicine, accessed June 28, 2025, [https://www.ccjm.org/content/82/6/373](https://www.ccjm.org/content/82/6/373)  
24. pulmonary embolism vs heart attack help : r/ems \- Reddit, accessed June 28, 2025, [https://www.reddit.com/r/ems/comments/1enlq6g/pulmonary\_embolism\_vs\_heart\_attack\_help/](https://www.reddit.com/r/ems/comments/1enlq6g/pulmonary_embolism_vs_heart_attack_help/)  
25. Takotsubo Cardiomyopathy: An ST-Elevation Myocardial Infarction Mimic \- PubMed, accessed June 28, 2025, [https://pubmed.ncbi.nlm.nih.gov/33952877/](https://pubmed.ncbi.nlm.nih.gov/33952877/)  
26. Takotsubo Cardiomyopathy \- ECG Library Diagnosis \- LITFL, accessed June 28, 2025, [https://litfl.com/takotsubo-cardiomyopathy-ecg-library/](https://litfl.com/takotsubo-cardiomyopathy-ecg-library/)  
27. Thoracic Aortic Dissection \- SAEM, accessed June 28, 2025, [https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m4-curriculum/group-m4-cardiovascular/thoracic-aortic-dissection](https://www.saem.org/about-saem/academies-interest-groups-affiliates2/cdem/for-students/online-education/m4-curriculum/group-m4-cardiovascular/thoracic-aortic-dissection)  
28. A case of ascending aortic dissection mimicking acute myocardial infarction and complicated with pericardial tamponade \- Cardiovascular Diagnosis and Therapy, accessed June 28, 2025, [https://cdt.amegroups.org/article/view/8276/html](https://cdt.amegroups.org/article/view/8276/html)  
29. Pulmonary Embolism Presenting as ST-Elevation Myocardial Infarction: A Diagnostic Trap, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7709082/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7709082/)  
30. STEMI or Pericarditis? How to Tell the Difference \- האיגוד הישראלי לרפואה דחופה, accessed June 28, 2025, [https://emergencymed.org.il/stemi-or-pericarditis-how-to-tell-the-difference/articles-2/](https://emergencymed.org.il/stemi-or-pericarditis-how-to-tell-the-difference/articles-2/)  
31. STEMI or Pericarditis? How to Tell the Difference \- JournalFeed, accessed June 28, 2025, [https://journalfeed.org/article-a-day/2022/stemi-or-pericarditis-how-to-tell-the-difference/](https://journalfeed.org/article-a-day/2022/stemi-or-pericarditis-how-to-tell-the-difference/)  
32. Pericarditis \- ECG Library \- LITFL, accessed June 28, 2025, [https://litfl.com/pericarditis-ecg-library/](https://litfl.com/pericarditis-ecg-library/)  
33. Pulmonary Emboli Mimicking ST-Elevation Myocardial Infarction Patterns \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11606358/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11606358/)  
34. Two EKG patterns of pulmonary embolism which mimic MI \- EMCrit Project, accessed June 28, 2025, [https://emcrit.org/pulmcrit/two-ekg-patterns-of-pulmonary-embolism-which-mimic-mi/](https://emcrit.org/pulmcrit/two-ekg-patterns-of-pulmonary-embolism-which-mimic-mi/)  
35. Takotsubo cardiomyopathy vs acute myocardial infarction: diagnostic utility of subtle ECG differences \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3094360/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3094360/)  
36. ECG Criteria to Differentiate Between Takotsubo (Stress) Cardiomyopathy and Myocardial Infarction | Journal of the American Heart Association, accessed June 28, 2025, [https://www.ahajournals.org/doi/10.1161/JAHA.116.003418](https://www.ahajournals.org/doi/10.1161/JAHA.116.003418)  
37. EKG: Pericarditis vs. STEMI \- Rush Emergency Medicine, accessed June 28, 2025, [https://rushem.org/2019/01/20/ekg-pericarditis-vs-stemi/](https://rushem.org/2019/01/20/ekg-pericarditis-vs-stemi/)  
38. Differentiating STEMI from Pericarditis \- JournalFeed, accessed June 28, 2025, [https://journalfeed.org/article-a-day/2020/differentiating-stemi-from-pericarditis/](https://journalfeed.org/article-a-day/2020/differentiating-stemi-from-pericarditis/)  
39. Cardiac troponin I (TnI) and T (TnT): Interpretation and evaluation in acute coronary syndromes – The Cardiovascular \- ECGWaves, accessed June 28, 2025, [https://ecgwaves.com/topic/cardiac-troponin-i-tni-and-t-tnt-interpretation-and-evaluation-in-acute-coronary-syndromes/](https://ecgwaves.com/topic/cardiac-troponin-i-tni-and-t-tnt-interpretation-and-evaluation-in-acute-coronary-syndromes/)  
40. ST-Elevation Myocardial Infarction (STEMI) \- DynaMed, accessed June 28, 2025, [https://www.dynamed.com/condition/st-elevation-myocardial-infarction-stemi-1](https://www.dynamed.com/condition/st-elevation-myocardial-infarction-stemi-1)  
41. An uncommon acute type A aortic dissection mimicking an inferior STEMI \- Pan African Medical Journal, accessed June 28, 2025, [https://www.panafrican-med-journal.com/content/article/36/247/full/](https://www.panafrican-med-journal.com/content/article/36/247/full/)  
42. litfl.com, accessed June 28, 2025, [https://litfl.com/pericarditis-ecg-library/\#:\~:text=Pericarditis%20can%20cause%20localised%20ST,II%20strongly%20suggests%20a%20STEMI.](https://litfl.com/pericarditis-ecg-library/#:~:text=Pericarditis%20can%20cause%20localised%20ST,II%20strongly%20suggests%20a%20STEMI.)  
43. High-sensitivity Troponins \- Difficult Friends in Acute Coronary Syndromes | ECR Journal, accessed June 28, 2025, [https://www.ecrjournal.com/articles/high-sensitivity-troponins-difficult-friends-acute-coronary-syndromes?language\_content\_entity=en](https://www.ecrjournal.com/articles/high-sensitivity-troponins-difficult-friends-acute-coronary-syndromes?language_content_entity=en)  
44. Serial high-sensitivity cardiac troponin T measurements to rule out acute myocardial infarction and a single high baseline measurement for swift rule-in: A systematic review and meta-analysis \- Oxford Academic, accessed June 28, 2025, [https://academic.oup.com/ehjacc/article/9/1/14/5933837](https://academic.oup.com/ehjacc/article/9/1/14/5933837)  
45. Secondary prevention following myocardial infarction: a clinical update \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5819978/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5819978/)  
46. Heart attack \- Diagnosis & treatment \- Mayo Clinic, accessed June 28, 2025, [https://www.mayoclinic.org/diseases-conditions/heart-attack/diagnosis-treatment/drc-20373112](https://www.mayoclinic.org/diseases-conditions/heart-attack/diagnosis-treatment/drc-20373112)  
47. ST elevation myocardial infarction chest x ray \- wikidoc, accessed June 28, 2025, [https://www.wikidoc.org/index.php/ST\_elevation\_myocardial\_infarction\_chest\_x\_ray](https://www.wikidoc.org/index.php/ST_elevation_myocardial_infarction_chest_x_ray)  
48. Acute coronary syndrome | Radiology Reference Article | Radiopaedia.org, accessed June 28, 2025, [https://radiopaedia.org/articles/acute-coronary-syndrome](https://radiopaedia.org/articles/acute-coronary-syndrome)  
49. Wall motion changes in myocardial infarction in relation to the time elapsed from symptoms until revascularization \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5779171/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5779171/)  
50. Prognostic impact of changes in left ventricular ejection fraction and wall motion score index in patients with myocardial infarction \- Frontiers, accessed June 28, 2025, [https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1530006/full](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1530006/full)  
51. Wall motion changes in myocardial infarction in relation to the time elapsed from symptoms until revascularization, accessed June 28, 2025, [https://anatoljcardiol.com/article/AJC-03688/pdf](https://anatoljcardiol.com/article/AJC-03688/pdf)  
52. The Prognostic Value of Echocardiographic Wall Motion Score Index in ST-Segment Elevation Myocardial Infarction, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9671736/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9671736/)  
53. Secondary prevention post myocardial infarction (Guidelines) \- Right Decisions, accessed June 28, 2025, [https://rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/adult-therapeutic-guidelines/cardiovascular/ischaemic-heart-disease/secondary-prevention-post-myocardial-infarction-guidelines/](https://rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/adult-therapeutic-guidelines/cardiovascular/ischaemic-heart-disease/secondary-prevention-post-myocardial-infarction-guidelines/)  
54. Point-of-Care Echo: Regional Wall Motion Abnormalities \- YouTube, accessed June 28, 2025, [https://www.youtube.com/watch?v=TWviIgG2V60\&pp=0gcJCdgAo7VqN5tD](https://www.youtube.com/watch?v=TWviIgG2V60&pp=0gcJCdgAo7VqN5tD)  
55. Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association | Circulation, accessed June 28, 2025, [https://www.ahajournals.org/doi/10.1161/CIR.0000000000000959](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000959)  
56. Management of ST-elevation myocardial infarction according to European and American guidelines | EuroIntervention, accessed June 28, 2025, [https://eurointervention.pcronline.com/article/management-of-st-elevation-myocardial-infarction-according-to-european-and-american-guidelines](https://eurointervention.pcronline.com/article/management-of-st-elevation-myocardial-infarction-according-to-european-and-american-guidelines)  
57. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the ..., accessed June 28, 2025, [https://bookcafe.yuntsg.com/ueditor/jsp/upload/file/20250305/1741139886862023760.pdf](https://bookcafe.yuntsg.com/ueditor/jsp/upload/file/20250305/1741139886862023760.pdf)  
58. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \- JACC Journals, accessed June 28, 2025, [https://www.jacc.org/doi/10.1016/j.jacc.2021.09.005](https://www.jacc.org/doi/10.1016/j.jacc.2021.09.005)  
59. 2025 Acute Coronary Syndromes Guideline-at-a-Glance \- JACC Journals, accessed June 28, 2025, [https://www.jacc.org/doi/10.1016/j.jacc.2025.01.018](https://www.jacc.org/doi/10.1016/j.jacc.2025.01.018)  
60. AHA, ACC Update Guidelines for Acute Coronary Syndrome Management, accessed June 28, 2025, [https://www.ajmc.com/view/aha-acc-update-guidelines-for-acute-coronary-syndrome-management](https://www.ajmc.com/view/aha-acc-update-guidelines-for-acute-coronary-syndrome-management)  
61. ESC recommendations on acute care and secondary prevention \- Medizinonline, accessed June 28, 2025, [https://medizinonline.com/en/esc-recommendations-on-acute-care-and-secondary-prevention/](https://medizinonline.com/en/esc-recommendations-on-acute-care-and-secondary-prevention/)  
62. New Guideline on Acute Coronary Syndromes: Key Takeaways for Cardiologists, accessed June 28, 2025, [https://consultqd.clevelandclinic.org/new-guideline-on-acute-coronary-syndromes-key-takeaways-for-cardiologists](https://consultqd.clevelandclinic.org/new-guideline-on-acute-coronary-syndromes-key-takeaways-for-cardiologists)  
63. Contemporary Management of Cardiogenic Shock Complicating Acute Myocardial Infarction, accessed June 28, 2025, [https://www.mdpi.com/2077-0383/12/6/2184](https://www.mdpi.com/2077-0383/12/6/2184)  
64. Management of cardiogenic shock complicating ST-segment elevation myocardial infarction: part 1 \- Journal Of Paramedic Practice, accessed June 28, 2025, [https://www.paramedicpractice.com/content/features/management-of-cardiogenic-shock-complicating-st-segment-elevation-myocardial-infarction-part-1/](https://www.paramedicpractice.com/content/features/management-of-cardiogenic-shock-complicating-st-segment-elevation-myocardial-infarction-part-1/)  
65. Management of cardiogenic shock complicating acute myocardial infarction: A review \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6712338/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6712338/)  
66. Cardiogenic Shock \- StatPearls \- NCBI Bookshelf, accessed June 28, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK482255/](https://www.ncbi.nlm.nih.gov/books/NBK482255/)  
67. Management of cardiogenic shock complicating myocardial infarction: an update 2019 | European Heart Journal | Oxford Academic, accessed June 28, 2025, [https://academic.oup.com/eurheartj/article/40/32/2671/5528526](https://academic.oup.com/eurheartj/article/40/32/2671/5528526)  
68. Management of cardiogenic shock: a narrative review \- PMC \- PubMed Central, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10980676/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10980676/)  
69. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee \- JACC Journals, accessed June 28, 2025, [https://www.jacc.org/doi/10.1016/j.jacc.2025.02.018](https://www.jacc.org/doi/10.1016/j.jacc.2025.02.018)  
70. Management of Cardiogenic Shock in Patients with Acute Myocardial Infarction \- Henry Ford Health Scholarly Commons, accessed June 28, 2025, [https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?article=1782\&context=cardiology\_articles](https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?article=1782&context=cardiology_articles)  
71. Early and late ventricular arrhythmias complicating ST-segment elevation myocardial infarction, accessed June 28, 2025, [https://www.sfcardio.fr/wp-content/uploads/2024/10/sfc-acvd-0122.pdf](https://www.sfcardio.fr/wp-content/uploads/2024/10/sfc-acvd-0122.pdf)  
72. Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10228619/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10228619/)  
73. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force \- European Society of Cardiology, accessed June 28, 2025, [https://www.escardio.org/static-file/Escardio/Subspecialty/EAPCI/ahead\_of\_print\_issue-article\_201408-19.pdf](https://www.escardio.org/static-file/Escardio/Subspecialty/EAPCI/ahead_of_print_issue-article_201408-19.pdf)  
74. Ventricular arrhythmias during ST-segment elevation myocardial infarction and arrhythmic complications during recurrent ischaemic events | European Heart Journal | Oxford Academic, accessed June 28, 2025, [https://academic.oup.com/eurheartj/article/45/5/393/7343151](https://academic.oup.com/eurheartj/article/45/5/393/7343151)  
75. Long-term clinical management after an acute coronary syndrome, accessed June 28, 2025, [https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopractice/long-term-clinical-management-after-an-acute-coronary-syndrome](https://www.escardio.org/Councils/Council-for-Cardiology-Practice-\(CCP\)/Cardiopractice/long-term-clinical-management-after-an-acute-coronary-syndrome)  
76. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence \- Oxford Academic, accessed June 28, 2025, [https://academic.oup.com/eurjpc/article/17/5/576/5932130](https://academic.oup.com/eurjpc/article/17/5/576/5932130)  
77. ACC/AHA Release Guidelines on Management of Patients With STEMI: Hospital and Long-Term Management | AAFP, accessed June 28, 2025, [https://www.aafp.org/pubs/afp/issues/2004/1115/p2011.html](https://www.aafp.org/pubs/afp/issues/2004/1115/p2011.html)  
78. Cardiac Rehabilitation \- StatPearls \- NCBI Bookshelf, accessed June 28, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK537196/](https://www.ncbi.nlm.nih.gov/books/NBK537196/)  
79. SECONDARY PREVENTION AFTER MYOCARDIAL INFARCTION: \- Key messages \- European Society of Cardiology, accessed June 28, 2025, [https://www.escardio.org/static-file/Escardio/Medias/associations/european-association-for-cardiovascular-prevention-and-rehabilitation/SPMI-key-recommendations-web.pdf](https://www.escardio.org/static-file/Escardio/Medias/associations/european-association-for-cardiovascular-prevention-and-rehabilitation/SPMI-key-recommendations-web.pdf)  
80. Secondary Prevention after Myocardial Infarction: What to Do and Where to Do It \- PMC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11273751/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11273751/)  
81. Part 1—Cardiac Rehabilitation After an Acute Myocardial Infarction: Four Phases of the Programme—Where Do We Stand? \- MDPI, accessed June 28, 2025, [https://www.mdpi.com/2077-0383/14/4/1117](https://www.mdpi.com/2077-0383/14/4/1117)  
82. Exercise Training and Cardiac Rehabilitation in Patients After Percutaneous Coronary Intervention: Comprehensive Assessment and Prescription \- MDPI, accessed June 28, 2025, [https://www.mdpi.com/2077-0383/14/5/1607](https://www.mdpi.com/2077-0383/14/5/1607)  
83. Cardiac Rehab and the Effects of Exercise Post STEMI \- American Heart Association, accessed June 28, 2025, [https://www.heart.org/-/media/Files/Affiliates/MWA/North-Dakota/North-Dakota-Stroke-Cardiac-Conference/Cardiac-Presentations/Cardiac-Rehab-and-the-Effects-of-Exercise-Post-STEMI.pdf](https://www.heart.org/-/media/Files/Affiliates/MWA/North-Dakota/North-Dakota-Stroke-Cardiac-Conference/Cardiac-Presentations/Cardiac-Rehab-and-the-Effects-of-Exercise-Post-STEMI.pdf)  
84. Cardiac Rehab: Phases & Exercises To Help Your Heart \- Cleveland Clinic, accessed June 28, 2025, [https://my.clevelandclinic.org/health/treatments/22069-cardiac-rehab](https://my.clevelandclinic.org/health/treatments/22069-cardiac-rehab)  
85. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes, accessed June 28, 2025, [https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309)  
86. Cardiac rehabilitation \- Mayo Clinic, accessed June 28, 2025, [https://www.mayoclinic.org/tests-procedures/cardiac-rehabilitation/about/pac-20385192](https://www.mayoclinic.org/tests-procedures/cardiac-rehabilitation/about/pac-20385192)  
87. Cardiac Rehabilitation \- Physiopedia, accessed June 28, 2025, [https://www.physio-pedia.com/Cardiac\_Rehabilitation](https://www.physio-pedia.com/Cardiac_Rehabilitation)  
88. First in a series on myocardial infarction: Secondary prevention after MI \- the role of the Junior Doctor, accessed June 28, 2025, [https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/First-in-a-series-on-myocardial-infarction-Secondary-prevention-after-MI-the-role-of-the-Junior-Doctor](https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/First-in-a-series-on-myocardial-infarction-Secondary-prevention-after-MI-the-role-of-the-Junior-Doctor)  
89. AHA/ACCF Guideline \- Arkansas Health & Wellness, accessed June 28, 2025, [https://www.arhealthwellness.com/content/dam/centene/Sunshine/pdfs/5\_2458.full%20(1).pdf](https://www.arhealthwellness.com/content/dam/centene/Sunshine/pdfs/5_2458.full%20\(1\).pdf)  
90. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \- PubMed, accessed June 28, 2025, [https://pubmed.ncbi.nlm.nih.gov/40014670/](https://pubmed.ncbi.nlm.nih.gov/40014670/)  
91. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes \- American Heart Association Journals, accessed June 28, 2025, [https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001309](https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001309)  
92. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes \- Professional Heart Daily, accessed June 28, 2025, [https://professional.heart.org/en/science-news/2025-guideline-for-the-management-of-patients-with-acute-coronary-syndromes](https://professional.heart.org/en/science-news/2025-guideline-for-the-management-of-patients-with-acute-coronary-syndromes)  
93. Acute Coronary Syndromes Guideline Hub \- JACC Journals, accessed June 28, 2025, [https://www.jacc.org/guidelines/acute-coronary-syndromes](https://www.jacc.org/guidelines/acute-coronary-syndromes)  
94. 2023 ESC Guidelines for the management of acute coronary ..., accessed June 28, 2025, [https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Coronary-Syndromes-ACS-Guidelines](https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Coronary-Syndromes-ACS-Guidelines)  
95. 2023 ESC Guidelines for the management of acute coronary syndromes Supplementary data, accessed June 28, 2025, [https://www.uniklinik-ulm.de/fileadmin/default/09\_Sonstige/Klinische-Chemie/Downloads/ehad191\_supplementary\_data\_ESC\_Guideline\_ACS\_2023.pdf](https://www.uniklinik-ulm.de/fileadmin/default/09_Sonstige/Klinische-Chemie/Downloads/ehad191_supplementary_data_ESC_Guideline_ACS_2023.pdf)  
96. 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes: Statement of endorsement by the NVVC, accessed June 28, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11413259/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11413259/)  
97. 2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic, accessed June 28, 2025, [https://academic.oup.com/eurheartj/article/44/38/3720/7243210](https://academic.oup.com/eurheartj/article/44/38/3720/7243210)  
98. Consensus Recommendations of the Asia Pacific Cardiometabolic Consortium on Secondary Prevention Strategies in Myocardial Infarction: Recommendations on Pharmacotherapy, Lifestyle Modification and Cardiac Rehabilitation, accessed June 28, 2025, [https://www.japscjournal.com/articles/consensus-recommendations-asia-pacific-cardiometabolic-consortium-secondary-prevention?language\_content\_entity=en](https://www.japscjournal.com/articles/consensus-recommendations-asia-pacific-cardiometabolic-consortium-secondary-prevention?language_content_entity=en)  
99. The 2021 AHA/ACC/SCAI Coronary Artery Revascularization Recommendations: Need for Emphasis on Prevention and Future Considerations \- JACC Journals, accessed June 28, 2025, [https://www.jacc.org/doi/10.1016/j.jacadv.2022.100006](https://www.jacc.org/doi/10.1016/j.jacadv.2022.100006)